Novo Nordisk AS (NVO)
101.56
-3.76
(-3.57%)
USD |
NYSE |
Nov 15, 09:40
Novo Nordisk Net Income (TTM): 13.79B for Sept. 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 13.79B |
| June 30, 2024 | 13.05B |
| March 31, 2024 | 12.99B |
| December 31, 2023 | 12.15B |
| September 30, 2023 | 10.85B |
| June 30, 2023 | 9.516B |
| March 31, 2023 | 8.583B |
| December 31, 2022 | 7.869B |
| September 30, 2022 | 7.676B |
| June 30, 2022 | 7.647B |
| March 31, 2022 | 7.705B |
| December 31, 2021 | 7.608B |
| September 30, 2021 | 7.425B |
| June 30, 2021 | 7.121B |
| March 31, 2021 | 6.726B |
| December 31, 2020 | 6.436B |
| September 30, 2020 | 6.235B |
| June 30, 2020 | 6.136B |
| March 31, 2020 | 6.011B |
| December 31, 2019 | 5.844B |
| September 30, 2019 | 5.851B |
| June 30, 2019 | 5.741B |
| March 31, 2019 | 5.955B |
| December 31, 2018 | 6.139B |
| September 30, 2018 | 6.146B |
| Date | Value |
|---|---|
| June 30, 2018 | 6.281B |
| March 31, 2018 | 6.095B |
| December 31, 2017 | 5.776B |
| September 30, 2017 | 5.732B |
| June 30, 2017 | 5.658B |
| March 31, 2017 | 5.700B |
| December 31, 2016 | 5.642B |
| September 30, 2016 | 5.592B |
| June 30, 2016 | 5.371B |
| March 31, 2016 | 5.093B |
| December 31, 2015 | 5.191B |
| September 30, 2015 | 5.075B |
| June 30, 2015 | 4.983B |
| March 31, 2015 | 5.033B |
| December 31, 2014 | 4.722B |
| September 30, 2014 | 4.731B |
| June 30, 2014 | 4.715B |
| March 31, 2014 | 4.610B |
| December 31, 2013 | 4.483B |
| September 30, 2013 | 4.379B |
| June 30, 2013 | 4.190B |
| March 31, 2013 | 3.934B |
| December 31, 2012 | 3.698B |
| September 30, 2012 | 3.546B |
| June 30, 2012 | 3.391B |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
5.844B
Minimum
Dec 2019
13.79B
Maximum
Sep 2024
8.568B
Average
7.661B
Median
Net Income (TTM) Benchmarks
| Ascendis Pharma AS | -530.29M |
| Amgen Inc | 4.23B |
| AstraZeneca PLC | 6.44B |
| Grifols SA | 216.85M |
| Viking Therapeutics Inc | -99.15M |